13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001795097
Total reported value
$544.2M
$544.2M
64 檔
47.2%
The Q4 2024 SEC filing reveals that Privium Fund Management B.V. held a total portfolio value of $544.2M, covering 64 public equity positions.
During Q4 2024, Privium Fund Management B.V.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TSLA | Tesla Inc | Stock-Consumer Disc | 20.10% | +0.44% | +1.85% | |
| 2 | SPOT | Spotify Technology S.A. | Stock-Comm Services | 14.68% | -2.12% | -2.68% | |
| 3 | SHOP | Shopify Inc - Class A | Stock-Tech | 9.99% | -2.29% | — | |
| 4 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 7.00% | +0.71% | — | |
| 5 | PLTR | Palantir Technologies Inc-a | Stock-Tech | 6.33% | -1.80% | -22.11% | |
| 6 | SE | Sea Ltd-adr | Stock-Comm Services | 5.04% | -2.38% | EXIT | |
| 7 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 2.99% | +0.05% | -11.48% | |
| 8 | QURE | uniQure N.V. | Stock-Other | 2.97% | +1.12% | -0.37% | |
| 9 | SNOW | Snowflake Inc | Stock-Tech | 2.62% | — | -21.05% | |
| 10 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.46% | +0.49% | +6.54% | |
| 11 | NVDA | Nvidia CORP | Stock-Tech | 2.22% | +0.04% | — | |
| 12 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.11% | +0.13% | +6.40% | |
| 13 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.84% | — | -17.65% | |
| 14 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.63% | — | +20.79% | |
| 15 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.62% | -1.28% | +14.17% | |
| 16 | NET | Cloudflare Inc - Class A | Stock-Tech | 1.46% | — | — | |
| 17 | SMR | Nuscale Power CORP | Stock-Industrials | 1.46% | — | — | |
| 18 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.19% | -0.27% | -22.43% | |
| 19 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.13% | -0.03% | +34.89% | |
| 20 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.10% | -0.09% | -14.17% | |
| 21 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.03% | +0.35% | — | |
| 22 | IONQ-WS | Ionq Inc -cw26 | Stock-Other | 0.88% | — | — | |
| 23 | MRNA | Moderna Inc | Stock-Healthcare | 0.78% | +0.07% | +103.73% | |
| 24 | CPNG | Coupang Inc | Stock-Consumer Disc | 0.71% | — | -29.72% | |
| 25 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.62% | — | — | |
| 26 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.58% | — | -55.52% | |
| 27 | ASTS | Ast Spacemobile Inc | Stock-Tech | 0.53% | -0.13% | -86.42% | |
| 28 | MSFT | Microsoft CORP | Stock-Tech | 0.48% | — | -50.00% | |
| 29 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.33% | +0.16% | +45.67% | |
| 30 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.31% | +0.03% | +15.32% | |
| 31 | MGTX | MeiraGTx Holdings plc | Stock-Other | 0.31% | +0.11% | +5.20% | |
| 32 | ABEV | Ambev Sa-adr | Stock-Consumer Staples | 0.27% | -0.12% | +4.83% | |
| 33 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.25% | -0.10% | +80.20% | |
| 34 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.21% | — | +24.61% | |
| 35 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.21% | -0.11% | — | |
| 36 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.19% | — | — | |
| 37 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.18% | — | +52.56% | |
| 38 | CMPOW | Composecure Inc -cw25 | Stock-Other | 0.16% | — | — | |
| 39 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.15% | -0.11% | +22.84% | |
| 40 | VAL | Valaris Limited | Stock-Energy | 0.14% | — | +86.34% | |
| 41 | NOV | Nov Inc | Stock-Energy | 0.14% | -0.02% | +13.09% | |
| 42 | AIG | American International Group | Stock-Financials | 0.13% | — | — | |
| 43 | PFE | Pfizer Inc | Stock-Healthcare | 0.13% | -0.31% | EXIT | |
| 44 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.12% | +0.01% | +24.80% | |
| 45 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.11% | — | +35.63% | |
| 46 | PAAS | Pan American Silver CORP | Stock-Materials | 0.10% | -0.04% | EXIT | |
| 47 | URNM | Sprott Uranium Miners ETF | ETF-Other | 0.09% | -0.04% | EXIT | |
| 48 | SEA1EUR | Seabridge Gold Inc | Stock-Other | 0.09% | -0.15% | EXIT | |
| 49 | EMX | Emx Royalty CORP | Stock-Other | 0.08% | — | — | |
| 50 | FNV | Franco-nevada CORP | Stock-Materials | 0.08% | — | -50.88% |
According to official SEC Form 13F filings, Privium Fund Management B.V. reported a total U.S. public equity portfolio value of $544.2M across 64 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TSLA, SPOT, SHOP) accounted for 47.2% of total reported equity market value during Q4 2024.
During Q4 2024, Privium Fund Management B.V.'s top holdings by market value included TSLA (20.1%)、SPOT (14.7%)、SHOP (10.0%). The largest single position, TSLA, represented 20.1% of total portfolio value.
In Q4 2024, Privium Fund Management B.V. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.